|
Post by lakers on Oct 14, 2017 12:00:14 GMT -5
|
|
|
Post by brotherm1 on Oct 14, 2017 12:15:36 GMT -5
Is that inhalation pump meant for people or elephants?
|
|
|
Post by dreamboatcruise on Oct 14, 2017 13:42:30 GMT -5
Is that inhalation pump meant for people or elephants? Are you talking about the image of Mannkind's old Medtone inhaler shown on that page?
|
|
|
Post by seanismorris on Oct 14, 2017 13:51:04 GMT -5
I wonder why they showed the Medtone inhaler? And, not the picture of what was seeking approval...
And, yes the old device was hideous...
|
|
|
What if?
Oct 14, 2017 13:56:42 GMT -5
via mobile
Post by brotherm1 on Oct 14, 2017 13:56:42 GMT -5
Is that inhalation pump meant for people or elephants? Are you talking about the image of Mannkind's old Medtone inhaler shown on that page? Oh, I suppose I was. Darn, my ignorance was bliss there for a while.
|
|
|
Post by brentie on Oct 14, 2017 14:05:21 GMT -5
I wonder why they showed the Medtone inhaler? And, not the picture of what was seeking approval... And, yes the old device was hideous... It could have been worse.
|
|
|
Post by captainwalker on Oct 14, 2017 14:08:55 GMT -5
^^^ Ha ha.... is that the Exubera inhaler in your pants or are you just happy to see me?
|
|
|
Post by kc on Oct 14, 2017 14:15:23 GMT -5
|
|
|
What if?
Oct 14, 2017 14:51:05 GMT -5
kc likes this
Post by dreamboatcruise on Oct 14, 2017 14:51:05 GMT -5
kc... it's hard to craft a win-win deal with an incumbent when you truly have technology that will in all likelihood cannibalize their existing market entirely. MNKD, unless desperate for cash, would see little reason to be generous, and this other company would likely do what is in their short term interest rather than looking at the long term... milk the market as long as they can and hope that Mannkind continues to be delayed in getting their product out.
|
|
|
What if?
Oct 14, 2017 15:19:34 GMT -5
via mobile
Post by brotherm1 on Oct 14, 2017 15:19:34 GMT -5
This article is almost two years old. I think Cipla might be the largest biopharma in the world. I wonder if they dropped the attempt with their own inhalable insulin.
|
|
|
Post by lakers on Oct 14, 2017 19:02:27 GMT -5
This article is almost two years old. I think Cipla might be the largest biopharma in the world. I wonder if they dropped the attempt with their own inhalable insulin. Talking about Cipla, Upadhye said, “We have a very strong presence in South Africa’s private as well as tender market. Cipla is the 4th largest company in the private pharma market and 3rd overall, including tender business. United States is also our priority market and our focus will be to grow our US franchise disproportionately.” health.economictimes.indiatimes.com/news/pharma/the-state-of-pharmaceutical-industry-in-india-an-overview/60273583Key players in the global dry powder inhalers market are Orion, Novartis, MicroDose Therapeutx, Meda, Mannkind, Mantecorp, Hovione, GlaxoSmithKline, Civitas/Alkermes, Cipla, Chiesi, Boehringer Ingelheim, AstraZeneca, and Aerovance, among others. www.lanews.org/dry-powder-inhalers-market-industrial-forecast-on-global-industry-analysis-and-trends-till-2025/
|
|
|
What if?
Oct 14, 2017 20:53:03 GMT -5
via mobile
Post by brotherm1 on Oct 14, 2017 20:53:03 GMT -5
This article is almost two years old. I think Cipla might be the largest biopharma in the world. I wonder if they dropped the attempt with their own inhalable insulin. Talking about Cipla, Upadhye said, “We have a very strong presence in South Africa’s private as well as tender market. Cipla is the 4th largest company in the private pharma market and 3rd overall, including tender business. United States is also our priority market and our focus will be to grow our US franchise disproportionately.” health.economictimes.indiatimes.com/news/pharma/the-state-of-pharmaceutical-industry-in-india-an-overview/60273583Key players in the global dry powder inhalers market are Orion, Novartis, MicroDose Therapeutx, Meda, Mannkind, Mantecorp, Hovione, GlaxoSmithKline, Civitas/Alkermes, Cipla, Chiesi, Boehringer Ingelheim, AstraZeneca, and Aerovance, among others. www.lanews.org/dry-powder-inhalers-market-industrial-forecast-on-global-industry-analysis-and-trends-till-2025/Would a company in the dry powder inhaler business have an advantage over biotechs that are not if they were to partner or acquire MNKD?
|
|
|
What if?
Oct 14, 2017 20:58:41 GMT -5
via mobile
Post by figglebird on Oct 14, 2017 20:58:41 GMT -5
Yes - they would have superior bioavalibilty.
Often referred to as ss trade secret.
|
|
|
Post by babaoriley on Oct 15, 2017 0:50:23 GMT -5
^^^ Ha ha.... is that the Exubera inhaler in your pants or are you just happy to see me? One of the best posts ever!
|
|